FDA Approves Kresladi, the First Gene Therapy for Severe LAD-I

On March 26, 2026, the U.S. Food and Drug Administration approved Kresladi (marnetegragene autotemcel) from Rocket Pharmaceuticals. It's the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I). For families facing one of the rarest and most dangerous immune disorders in children, this is a turning point.

Kresladi is approved for children with severe LAD-I caused by mutations in both copies of the ITGB2 gene who don't have an HLA-matched sibling who could donate stem cells. That second condition matters. Until now, a stem cell transplant was the only real cure, and the best transplants come from a matched brother or sister. Many children don't have one.

An immune army that can't leave the barracks

To see why LAD-I is so dangerous, picture your white blood cells as soldiers patrolling the bloodstream. When bacteria invade a tissue, say a cut on the skin or the gums, the soldiers need to do three things. They slow down, grip the wall of the blood vessel, and squeeze through it to reach the fight.

The grip depends on a protein called CD18, a building block of adhesion molecules called β2 integrins. The ITGB2 gene holds the recipe for CD18. When both copies of ITGB2 are broken, neutrophils (the immune system's first responders) roll past the infection. They can't hold on, so they can't get out.

The result is a strange and telling picture. Children with severe LAD-I often have very high neutrophil counts in their blood, because the cells are stuck circulating. Yet their tissues are defenseless. Babies may have a delayed separation of the umbilical cord, severe skin and soft-tissue infections that don't form pus, poor wound healing, and serious gum disease. Without a successful transplant, many children with the severe form don't survive early childhood.

How Kresladi works: fixing the recipe at the source

If gene therapy is a Master Chef, Kresladi's job is to hand the kitchen a corrected copy of a missing recipe. In this case, the kitchen is the patient's own blood stem cells, which make every white blood cell the body will ever produce.

Kresladi is an ex vivo gene therapy, meaning the genetic fix happens outside the body. The process works in several steps:

1. Doctors collect the child's own hematopoietic (blood-forming) stem cells.

2. In the lab, a lentiviral vector delivers a working copy of ITGB2 into those cells. Think of the vector as a spaceship built to carry one precious cargo: the healthy gene. Lentiviral vectors can insert their cargo into the cell's DNA, so the correction is passed on every time the stem cell divides.

3. The child receives conditioning chemotherapy to clear space in the bone marrow.

4. The corrected cells go back in through a single intravenous infusion.

Because the cells are the patient's own, there's no need to find a donor. The risk of graft-versus-host disease, a serious complication of donor transplants in which donor immune cells attack the patient's body, also drops away.

What the evidence showed

The FDA based its decision on clinical data showing sustained improvements in the expression of neutrophil surface markers, meaning CD18 was being made again, through 24 months of follow-up. In practical terms, the corrected stem cells took hold and kept producing neutrophils that carry the protein they were missing.

The side effects reported included anemia, infections, mouth sores, and gastrointestinal symptoms. Many of these line up with what doctors expect from the conditioning chemotherapy that prepares the bone marrow.

Kresladi was granted accelerated approval. This pathway lets the FDA approve a therapy based on a measure that is reasonably likely to predict real clinical benefit, here, the restored neutrophil markers. In return, Rocket must run post-marketing studies to confirm that the benefit holds up. The FDA framed the decision around the realities of rare disease: the agency, it said, "considers small patient populations in clinical trials and all available sources of evidence to advance life-changing treatments."

Why this approval matters beyond LAD-I

LAD-I affects only a small number of children worldwide, so Kresladi will never be a blockbuster. Its importance lies elsewhere.

It proves the lentiviral stem cell model again. Lentiviral correction of blood stem cells already underpins approved therapies for conditions like beta-thalassemia and cerebral adrenoleukodystrophy. Each new approval shows the approach can be adapted from one blood-cell disorder to the next. For patients with other inherited immune deficiencies, that's encouraging.

It removes the donor bottleneck. For many children with inherited immune disorders, the question has always been "Is there a match?" A therapy built from a child's own cells changes the question entirely.

It shows how the FDA is treating ultra-rare disease. Trials in conditions this rare will never enroll hundreds of patients. The agency's willingness to lean on a meaningful biomarker, with confirmatory studies to follow, is a signal that other rare-disease developers are watching closely.

The questions that remain

There are still things to learn. Long-term follow-up will tell us how durable the correction is over decades, not years. As with all integrating vectors, researchers will keep watching for any signs that the inserted gene lands in a problematic spot in the genome. And, as with most one-time gene therapies, cost and access will shape how many eligible children actually receive it. Rocket had not highlighted pricing in the approval announcement.

Conditioning chemotherapy also remains a hurdle. It's one of the hardest parts of any stem-cell-based gene therapy. Gentler conditioning methods, such as antibody-based approaches, are an active area of research across the field. If they succeed, therapies like Kresladi could become easier on young patients.

The bottom line

For decades, a child born with severe LAD-I had an immune system that could see the enemy but couldn't reach it. Kresladi gives those children's own stem cells the missing piece: the grip that lets white blood cells leave the bloodstream and fight. It's a small approval by the numbers, and a very large one for the families it serves.

T.N